Artemis Therapeutics, Inc. (ATMS) Starts Presentation at LD Micro Main Event
Artemis Therapeutics (OTC: ATMS) is a clinical-stage biopharmaceutical company focused on the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. The company's lead product candidate, artemisone, is a synthetic artemisinin derivative with anti-viral and anti-parasitic properties. The company is currently evaluating artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (HCMV) infection, Artemis is also developing artemisone for the treatment of other virus and parasitic-related clinical indications. For more information, visit the company’s website at www.artemis-therapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news…







